New York based Adjuvant Capital has raised $300 million for a new fund to finance the development of affordable drugs, vaccines, diagnostics, and medical devices for diseases such as malaria, shigella, hookworm, HIV and tuberculosis. Historically these areas have been overlooked by the venture capital industry.
Adjuvant has already invested in 14 companies developing technologies for high-impact indications ranging from rare conditions, such as melioidosis, to widespread global emergencies, such as COVID-19.
“A wide array of private, public and philanthropic partners have come together to help ensure the most promising health technologies and services are available to people most in need,” said Mark Suzman, CEO of the Bill & Melinda Gates Foundation.
Read more from the press release.
Adjuvant is a global life sciences investment company built to accelerate the development of new technologies for the world’s most pressing public health challenges.